GoodRx Holdings, Inc. (GDRX)
| Market Cap | 1.71B |
| Revenue (ttm) | 790.39M |
| Net Income (ttm) | -16.22M |
| Shares Out | 384.80M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 25.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,210,952 |
| Open | 4.480 |
| Previous Close | 4.490 |
| Day's Range | 4.411 - 4.630 |
| 52-Week Range | 4.090 - 9.260 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | 9.00 (+102.7%) |
| Earnings Date | Nov 7, 2024 |
About GDRX
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves ph... [Read more]
Financial Performance
In 2023, GoodRx Holdings's revenue was $750.27 million, a decrease of -2.12% compared to the previous year's $766.55 million. Losses were -$8.87 million, -72.99% less than in 2022.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for GDRX stock is "Buy." The 12-month stock price forecast is $9.0, which is an increase of 102.70% from the latest price.
News
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the...
GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today revealed startling healthcare disparities in its new report, “Endocrinologist...
GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President an...
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
Prescription fills for blockbuster weight loss medications in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments. That's according...
GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today released a new Weight Loss Medications Tracker that provides an inside look a...
GoodRx Helps Announces Recipients of 2024 Students for Healthcare Equity Scholarship
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Helps, a 501(c)(3) nonprofit organization seeking to address health inequities across the country, has selected its 2024 Students for Healthcare Equity Sc...
Kuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law Firm
NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached t...
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability...
GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript
GoodRx Reports Third Quarter 2024 Results
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its fin...
GoodRx and CVS Sued for Suppressing Pharmacy Reimbursement
Smaller pharmacies are accusing GoodRx and CVS of colluding to suppress generic prescription drug reimbursements. As Reuters reported Tuesday (Nov. 5), drug coupon aggregator GoodRx and a pair of phar...
GoodRx to Participate in Upcoming Investor Conferences
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the...
GoodRx Unveils New E-commerce Platform, Launches with Opill®
SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its lau...
GoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules ...
Ronald E. Bruehlman Joins GoodRx Board of Directors
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the e...
GoodRx Announces New Affordability Programs for Menopause Hormone Therapies
SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced the availability of new affordability programs for menopause hormo...
GoodRx Partnering with Retail Pharmacies to Deliver Pay-Over-Time Option Directly to Consumers
SAN FRANCISCO--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced consumers will soon be able to use Affirm to pay over time for select medi...
GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its thir...
GoodRx Holdings: Failing To Gain Much Traction
Today, we are circling back on GoodRx Holdings, which offers a platform for comparing prescription drug prices. The company also enables their customers to benefit from negotiated prices through GoodR...
GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. (“ARS Pharmaceuticals”...
GoodRX Subscription Revenue Down 8% but Active User Numbers Are Up
It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active user...
GoodRx Holdings, Inc. (GDRX) Q2 2024 Earnings Call Transcript
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Execu...
GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges
Prescription savings platform GoodRx Holdings Inc. GDRX reported second-quarter revenue of $200.61 million, up 6% year over year, almost in line with the consensus of $200.4 million.
GoodRx Reports Second Quarter 2024 Results
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its fin...
GoodRx Q2 Earnings Preview
GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance d...